Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Driven by positive top-line growth along with lower input costs, Brown-Forman Corporation ( BF.B - Analyst Report ) started the fiscal 2013 with strong first-quarter results. The company’s adjusted earnings for the quarter surged 27.8% to 69 cents per share from 54 cents earned in the previous-year quarter, beating the Zacks Consensus Estimate of 62 cents.
Quarterly Details
Brown-Forman's net sales grew 4% to $878.1 million compared with $840.3 million in the year-ago period primarily driven by price increase partially offset by adverse currency exchange rates and spin-off of Hopland wine business. On an underlying basis, the company’s net sales registered 10% growth year over year. However, quarterly sales were below the Zacks Consensus Estimate of $893 million.
During the quarter, Brown-Forman’s gross profit increased 10% to $464.1 million from $420.3 million primarily due to lower input costs. Consequently, gross margin improved 290 basis points (bps) to 52.9% compared with 50% in the prior-year period.
As a percentage of net sales, the company’s operating expenses grew 130 bps to 28.6% primarily due to deleveraged selling, general and administrative expenses, which increased 40 bps to 16.9%, partially offset by a leverage of 30 bps in advertising expenses.
Operating profit during the quarter increased 19% to $221.7 million from $185.9 in the prior-year period, primarily driven by improved gross profit, partially offset by increased operating expenses. Consequently, operating margin expanded 310 bps to 25.2% compared with 22.1% in the year-ago quarter.
Balance Sheet & Cash Flow
Brown-Forman ended the quarter with cash and cash equivalents of $361.5 million and long-term debt of $502.1 million. During the quarter, Brown-Forman generated $87.6 million of cash from operations and deployed $49.8 million for dividend payout and $17.4 million on capital expenditures.
Guidance
Moving forward, Brown-Forman confirmed its outlook for fiscal 2013. The company expects improvement in customer trends to continue in second quarter of fiscal 2013. However, it anticipates that the stronger U.S. dollar value may have an adverse impact on its bottom line.
Currently, Brown-Forman expects fiscal 2013 earnings in the range of $2.40 - $2.67 per share.
Our Recommendation
We believe Brown-Forman’s strategy of expanding Jack Daniel's market share in developed markets, such as France and the U.S., and emerging markets including Russia, Poland and Mexico, where the whiskey category is in early stages of development, will boost its top line.
However, apart from macroeconomic headwinds, distilled spirits are subject to excise tax in various countries. Rising fiscal pressure in the U.S., European and many emerging markets may lead to increasing risk of a potential excise tax on spirits by the governments of respective countries. The effect of hike in excise tax in the future may have an adverse effect on Brown-Forman’s financial performance.
Above all, the company faces intense competition from other well-established players in the industry, such as Beam Inc. ( BEAM - Snapshot Report ) , Constellation Brands Inc. ( STZ - Analyst Report ) and Diageo plc ( DEO - Analyst Report ) . Moreover, Brown-Forman encounters competition from local and regional players in the respective countries. Consequently, this may dent the company’s future operating performance.
Currently, Brown-Forman has a Zacks #3 Rank, which implies a short-term Hold rating. Moreover, we maintain a long-term ‘Neutral’ recommendation on the stock.
Read the full reports :
Analyst Report on BF.B
Analyst Report on STZ
Analyst Report on DEO
Snapshot Report on BEAM